^
Association details:
| Biomarker: | EGFR exon 18 mutation + EGFR exon 21 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1000P - Common and uncommon mutations in NSCLC: Differences in response to treatment with tyrosine kinase inhibitors: A single-center retrospective analysis
Published date:
09/05/2022
Excerpt:
48 patients with EGFR-positive NSCLC were identified and divided into subgroups by mutation. Progression-free survival (PFS), overall survival (OS) and time to treatment failure (TTF) in those who were treated with Afatinib (Giotrif®) were evaluated….Patients with mutations in exon 18 and 21 and patients with mutations in exon 20 had the worst outcome with an OS of 6.5 months (95% CI: 4-30) a PFS of 2.5 months (95% CI: 1-4) and an OS of 3 months (95% CI: 2-4) and a PFS of 4.5 (95% CI: 4-5), respectively. Patients with these mutations also had significantly lower TTF.
